Global Moderate and Severe Chronic Kidney Disease Pipeline Insight Report 2021 Featuring KBP-5074: KBP Biosciences & ELIXCYTE: UnicoCell Biomed - ResearchAndMarkets.com

The "Moderate and Severe Chronic Kidney Disease - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Moderate and Severe Chronic Kidney Disease - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Moderate and Severe Chronic Kidney Disease pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Moderate and Severe Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Moderate and Severe Chronic Kidney Disease.

Moderate and Severe Chronic Kidney Disease Emerging Drugs Chapters

This segment of the Moderate and Severe Chronic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Moderate and Severe Chronic Kidney Disease Emerging Drugs

• KBP-5074: KBP Biosciences

KBP-5074 is a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA) with a unique pharmacokinetic (PK) profile characterized by a longer half-life and increased mineralocorticoid receptor (MR) affinity than current MRAs. KBP-5074 is currently evaluating patients in a global Phase 2b study evaluating its ability to treat uncontrolled hypertension and cardiorenal disease in stage 3b/4 Chronic Kidney Disease (CKD) patients who are at high risk of hyperkalemia and for whom existing MRAs are contraindicated.

• ELIXCYTE: UnicoCell Biomed

ELIXCYTE is an allogeneic adipose stem cell product and is currently undergoing two human clinical trials. For chronic kidney disease (CKD) treatment (NCT02933827), the phase-II clinical trial is ongoing.

Moderate and Severe Chronic Kidney Disease: Therapeutic Assessment

This segment of the report provides insights about the different Moderate and Severe Chronic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Moderate and Severe Chronic Kidney Disease

There are approx. 4+ key companies which are developing the therapies for Moderate and Severe Chronic Kidney Disease. The companies which have their Moderate and Severe Chronic Kidney Disease drug candidates in the most advanced stage, i.e. phase II include, KBP Bioscience.

The report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Moderate and Severe Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Moderate and Severe Chronic Kidney Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Moderate and Severe Chronic Kidney Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Moderate and Severe Chronic Kidney Disease drugs.

Moderate and Severe Chronic Kidney Disease Report Insights

• Moderate and Severe Chronic Kidney Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Moderate and Severe Chronic Kidney Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Moderate and Severe Chronic Kidney Disease drugs?
• How many Moderate and Severe Chronic Kidney Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Moderate and Severe Chronic Kidney Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Moderate and Severe Chronic Kidney Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Moderate and Severe Chronic Kidney Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• KBP Bioscience
• UnicoCell Biomed

Key Products

• KBP-5074
• ELIXCYTE

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/mzytwp

View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005620/en/